chlorotrianisene
Trade name: tace
Chlorotrianisene (TACE®) is a powerful synthetic, non-steroidal estrogen used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. It may also be used to prevent breast engorgement following childbirth. Chlorotrianisene (TACE®) binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. — NCATS
Clinical trial activity
12 trials · 16 clinical orgs · 3 marketing orgs
Earliest trial started Jun 30, 2011 (NCT01300143)
Timeline
1950s
- Jun 1, 1951
Richardson Vicks Inc — First NDA Organization
- Jun 1, 1951
Richardson Vicks Inc — NDA Organization
Indications
Mechanism of action
- Estrogen receptor betaMODULATOR
ESR2 modulator
Mixed agonist/antagonist
Approval history
- approved—
Chemistry & pharmacology
SMILES
COC1=CC=C(C=C1)C(Cl)=C(C2=CC=C(OC)C=C2)C3=CC=C(OC)C=C3- Mol. weight
- 380.864 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaChlorotrianisene ↗
- NCATS6V5034L121 ↗
- ChEMBLCHEMBL1200761 ↗
Also known as
- chloortrianisestrol
- chloortrianisestrol
- chlorestrolo
- chlorestrolo
- chlorotrianisene
- chlorotrianisene
- chlorotrianisene
- chlorotrianisene
- chlorotrianisene
- chlorotrianisene
- chlorotrianisene
- chlorotrianisene
- chlorotrianisene
- chlorotrianisene
- chlorotrianisenum
- chlorotrianisenum
- chlorotrianisine
- chlorotrianisine
- chlorotrianizen
- chlorotrianizen
- chlortrianisen
- chlortrianisen
- chlortrianisestrol
- chlortrianisestrol
- chlortrianisestrol
- chlortrianisoestrolum
- chlortrianisoestrolum
- chlortrianizen
- chlortrianizen
- chlortrianizen
- clorotrianisene
- clorotrianiseno
- clorotrianiseno
- clorotrisin
- hormonisene
- khlortrianizen
- tace
- tace
- tace
- trianisestrol
- trianisestrol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06644937 | Phase 2/Phase 3 (Phase 3) | Oct 9, 2024 | Southern Medical University |
| NCT05883176 | Phase 2 | Jun 1, 2023 | Sun Yat-Sen University |
| NCT04981665 | Phase 2 | Sep 30, 2021 | China Medical University, Hainan People's Hospital, Shandong University, Southwest Medical University, Tianjin Medical University, Zhejiang University |
| NCT04954781 | Phase 2 | Jul 14, 2021 | Fudan University |
| NCT04954794 | Phase 2 | Jul 14, 2021 | Fudan University |
| NCT04653389 | Phase 2 | Dec 1, 2020 | Zhejiang University |
| NCT04297280 | Phase 2 | May 10, 2020 | Fudan University |
| NCT04174781 | Phase 2 | Nov 20, 2019 | Zhejiang University |
| NCT03572582 | Phase 2 | Jun 14, 2018 | AIO-Studien-gGmbH, Bristol-Myers Squibb, Medizinische Hochschule Hannover |
| NCT03783559 | Phase 3 | Jan 31, 2016 | Fudan University |
| NCT02568748 | Phase 3 | Oct 1, 2015 | Cairo University, Tanta University |
| NCT01300143 | Phase 2 | Jun 30, 2011 | CHU Henri Mondor, University of Nantes |
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 4 | 4 | 2 | 2016 |
| Zhejiang University | Academic/Hospital | 3 | 3 | 1 | 2019 |
| AIO-Studien-gGmbH | For profit | 1 | 1 | 1 | 2018 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| Cairo University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| CHU Henri Mondor | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Hainan People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Medizinische Hochschule Hannover | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Southern Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Southwest Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2011 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Banner Pharmacaps | For profit | MKTG | — |
| Richardson Vicks Inc | For profit | NDA | Jun 1, 1951 |
| Sanofi-Aventis | For profit | NDA2 | — |